David Delaney bought $1,110 of KTTA
other at Pasithea Therapeutics Corp.. 1,000 shares at an average of $1.11, traded Oct 17, 2022, filed Oct 19, 2022.
Score components
- +8RoleOther
- 0Trade size$1k at market
- -5Relative to holdingsUnder 1% of holdings (0.4%)
- +8Price context80% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001209191-22-054100, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 17, 2022 | POpen-market purchase Common Stockindirect: See footnote | +1,000 | $1.11 | $1,110 | 227,521 | Oct 19, 2022 |
Related signals
Other insiders at Pasithea Therapeutics Corp. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 22Weak | KTTAbuy Pasithea Therapeutics Corp. | Coastlands Capital LP owner | $53k 100,000 shares | +3% | |
| 40Moderate | Pasithea Therapeutics Corp. | Simon Dumesnil director | $25k 33,333 shares | +1333% | |
| 50Moderate | Pasithea Therapeutics Corp. | Tiago Marques Chief Executive Officer | $25k 33,333 shares | +83% | |
| 50Moderate | Pasithea Therapeutics Corp. | Lawrence Steinman director | $100k 133,333 shares | +201% | |
| 25Weak | KTTAsell Pasithea Therapeutics Corp. | Tiago Marques Chief Executive Officer | $792 960 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.